Loading...

Idera Pharmaceuticals, Inc.

IDRA•NASDAQ
Healthcare
Biotechnology
$0.42
$-0.13(-23.04%)

Idera Pharmaceuticals, Inc. (IDRA) Stock Overview

Explore Idera Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for IDRAStats details for IDRA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for IDRAAnalyst Recommendations details for IDRA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

CEO

Mr. Vincent J. Milano

Employees

13

Headquarters

505 Eagleview Boulevard, Exton, PA

Founded

1996

Frequently Asked Questions

;